Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-29 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB | ||
| 2023-12-29 00:00 |
풍문또는보도에대한해명(미확정)
|
Korean | 5.4 KB | ||
| 2023-12-29 00:00 |
투자판단관련주요경영사항(CT-P41(프롤리아&엑스지바 바이오시밀러) 한국 품목허가 신청)
|
Korean | 14.6 KB | ||
| 2023-12-28 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 7.4 KB | ||
| 2023-12-28 00:00 |
증권발행실적보고서(합병등)
|
Korean | 127.7 KB | ||
| 2023-12-28 00:00 |
대표이사(대표집행임원)변경(안내공시)
|
Korean | 6.1 KB | ||
| 2023-12-26 00:00 |
투자판단관련주요경영사항(유플라이마(CT-P17, 휴미라 바이오시밀러) 상호교환성 임상 3상 결과 발표)
|
Korean | 14.2 KB | ||
| 2023-12-15 00:00 |
투자판단관련주요경영사항(CT-P47(악템라 바이오시밀러) 임상 3상 결과 발표)
|
Korean | 13.3 KB | ||
| 2023-12-15 00:00 |
자기주식취득결과보고서
|
Korean | 31.8 KB | ||
| 2023-12-13 00:00 |
현금ㆍ현물배당결정
|
Korean | 9.8 KB | ||
| 2023-12-08 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 531.3 KB | ||
| 2023-12-06 00:00 |
투자판단관련주요경영사항(다중항체의 발굴 및 연구개발을 위한 공동 연구 계약 체결)
|
Korean | 11.4 KB | ||
| 2023-12-01 00:00 |
투자판단관련주요경영사항(CT-P41(프롤리아&엑스지바 바이오시밀러) 미국 품목허가 신청)
|
Korean | 15.0 KB | ||
| 2023-12-01 00:00 |
풍문또는보도에대한해명(미확정)
|
Korean | 4.7 KB | ||
| 2023-11-30 00:00 |
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 18.5 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
